A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions

MelanomaUrothelial CarcinomaRenal Cell CarcinomaNon-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Carcinoma

Interventions

DRUG

RC198 Injection

RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.

Trial Locations (5)

Cabrini Hospital Malvern, Malvern

ICON Cancer Centre Wesley, Auchenflower

Southern Oncology Clinical Research Unit, Bedford Park

Zhongnan Hospital of Wuhan University, Wuhan

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT05867303 - A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter